We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
It was only a month after Bristol-Myers Squibb kicked off 2019 by announcing it would buy Celgene for $74 billion that rumors emerged about activist hedge fund Starboard Value taking an interest in the deal—and not necessarily a positive one. Now those mu